Publications
Detailed Information
Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Eun Uk | - |
dc.contributor.author | Yoon, Jung-Hwan | - |
dc.contributor.author | Lee, Youn-Jae | - |
dc.contributor.author | Lee, Jeong-Hoon | - |
dc.contributor.author | Yu, Su Jong | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.contributor.author | Lee, Hyo-Suk | - |
dc.contributor.author | Myung, Sun Jung | - |
dc.contributor.author | Kim, Bo Hyun | - |
dc.date.accessioned | 2012-06-27T07:23:17Z | - |
dc.date.available | 2012-06-27T07:23:17Z | - |
dc.date.issued | 2010-12-01 | - |
dc.identifier.citation | CANCER LETTERS; Vol.298 1; 9-15 | ko_KR |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77627 | - |
dc.description.abstract | Hypoxia may activate survival signals in cancer cells. Moreover, hypoxic cells are less sensitive than normoxic cells to doxorubicin cytotoxicity, a potent activator of the p53 tumor suppressor gene. N-myc downstream-regulated gene-1 (NDRG1) is a hypoxia- and retinoic acid-inducible protein, and has been previously implicated in carcinogenesis. As this protein is also a downstream target of p53 and hepatocellular carcinoma (HCC) cells frequently evidence resistance to retinoic acid (RA) cytotoxicity, we attempted to determine whether the suppression of NDRG1 expression may sensitize HCC cells to doxorubicin and/or RA cytotoxicity. HCC cells expressed NDRG1 protein, and the expression of this protein was hypoxia- and RA-inducible. Doxorubicin treatment induced HCC cell cytotoxicity via the activation of mitochondrial apoptotic signals, including caspase-9 activation. Hypoxic HCC cells are less sensitive to doxorubicin-induced apoptosis. The suppression of NDRG1 expression either by siRNA or flavopiridol sensitized hypoxic HCC cells to doxorubicin cytotoxicity, and this was attributed to more profound augmentation of JNK and caspase-9 activation. The suppression of NDRG1 expression also sensitized RA-resistant HCC cells to RA-induced apoptosis, and this sensitization was more apparent in hypoxic HCC cells than in normoxic cells. Glutaredoxin2 expression was down-regulated in NDRG1-suppressed HCC cells. These results show that hypoxia- and RA-inducible NDRG1 expression is responsible for doxorubicin and RA resistance in HCC cells. Thus, the selective interruption of NDRG1 signaling may prove to be therapeutically useful in HCCs, particularly in the advanced infiltrative type of tumors exposed to hypoxic environments. (C) 2010 Elsevier Ireland Ltd. All rights reserved. | ko_KR |
dc.description.sponsorship | This study was supported by the
Seoul National University Hospital Research Fund (#06- 2007-0109) and the Korea Health 21 R&D Project (#0412-CR01-0704-0001). | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER IRELAND LTD | ko_KR |
dc.subject | Hepatocellular carcinoma | ko_KR |
dc.subject | Hypoxia | ko_KR |
dc.subject | Retinoic acid | ko_KR |
dc.subject | Doxorubicin | ko_KR |
dc.subject | N-myc downstream-regulated gene-1 | ko_KR |
dc.title | Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 정은욱 | - |
dc.contributor.AlternativeAuthor | 윤정환 | - |
dc.contributor.AlternativeAuthor | 이윤재 | - |
dc.contributor.AlternativeAuthor | 이정훈 | - |
dc.contributor.AlternativeAuthor | 김보현 | - |
dc.contributor.AlternativeAuthor | 유수정 | - |
dc.contributor.AlternativeAuthor | 명순정 | - |
dc.contributor.AlternativeAuthor | 김윤준 | - |
dc.contributor.AlternativeAuthor | 이효석 | - |
dc.identifier.doi | 10.1016/j.canlet.2010.05.020 | - |
dc.citation.journaltitle | CANCER LETTERS | - |
dc.description.citedreference | Koshiji M, 2007, WORLD J GASTROENTERO, V13, P2803 | - |
dc.description.citedreference | Tu LC, 2007, MOL CELL PROTEOMICS, V6, P575, DOI 10.1074/mcp.M600249-MCP200 | - |
dc.description.citedreference | Tezuka M, 2007, DIGEST DIS SCI, V52, P783, DOI 10.1007/s10620-006-9537-y | - |
dc.description.citedreference | Chua MS, 2007, MODERN PATHOL, V20, P76, DOI 10.1038/modpathol.3800711 | - |
dc.description.citedreference | Angst E, 2006, BRIT J CANCER, V95, P307, DOI 10.1038/sj.bjc.6603256 | - |
dc.description.citedreference | Zhou J, 2006, CANCER LETT, V237, P10, DOI 10.1016/j.canlet.2005.05.028 | - |
dc.description.citedreference | Myung SJ, 2006, HEPATO-GASTROENTEROL, V53, P266 | - |
dc.description.citedreference | Asmis R, 2005, FASEB J, V19, P1866, DOI 10.1096/fj.04-2991fje | - |
dc.description.citedreference | Richard C, 2005, CLIN CANCER RES, V11, P3523 | - |
dc.description.citedreference | Gwak GY, 2005, J HEPATOL, V42, P358, DOI 10.1016/j.jhep.2004.11.020 | - |
dc.description.citedreference | Matsuzawa A, 2005, ANTIOXID REDOX SIGN, V7, P472 | - |
dc.description.citedreference | Stein S, 2004, J BIOL CHEM, V279, P48930, DOI 10.1074/jbc.M400386200 | - |
dc.description.citedreference | Lillig CH, 2004, P NATL ACAD SCI USA, V101, P13227, DOI 10.1073/pnas.0401896101 | - |
dc.description.citedreference | Cangul H, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-27 | - |
dc.description.citedreference | Motwani M, 2002, CANCER RES, V62, P3950 | - |
dc.description.citedreference | Lopez RR, 2002, ARCH SURG-CHICAGO, V137, P653 | - |
dc.description.citedreference | Llovet JM, 2002, LANCET, V359, P1734 | - |
dc.description.citedreference | You KR, 2001, HEPATOLOGY, V34, P1119, DOI 10.1053/jhep.2001.29199 | - |
dc.description.citedreference | Gladyshev VN, 2001, J BIOL CHEM, V276, P30374 | - |
dc.description.citedreference | Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139 | - |
dc.description.citedreference | Xu B, 1999, BIOL REPROD, V61, P681 | - |
dc.description.citedreference | Piquemal D, 1999, BBA-MOL CELL RES, V1450, P364 | - |
dc.description.citedreference | Muto Y, 1999, NEW ENGL J MED, V340, P1046 | - |
dc.description.citedreference | vanBelzen N, 1997, LAB INVEST, V77, P85 | - |
dc.description.citedreference | Muto Y, 1996, NEW ENGL J MED, V334, P1561 | - |
dc.description.citedreference | Mise M, 1996, HEPATOLOGY, V23, P455 | - |
dc.description.citedreference | PARK JG, 1995, INT J CANCER, V62, P276 | - |
dc.description.citedreference | HUANG ME, 1988, BLOOD, V72, P567 | - |
dc.description.citedreference | LAI CL, 1988, CANCER, V62, P479 | - |
dc.description.citedreference | NAKABAYASHI H, 1982, CANCER RES, V42, P3858 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.